MBX Biosciences, Inc.

#ICYMI: Results from the Phase 1 study of MBX 2109, our once-weekly parathyroid hormone (PTH) peptide prodrug for the treatment of hypoparathyroidism (#HP), have been published in Endocrine Society The Journal of Clinical Endocrinology and Metabolism (JCEM)!   This peer-reviewed study highlights MBX 2109’s long half-life and steady exposure profile, which has the potential to provide a more consistent therapeutic effect while reducing calcium fluctuations that are often seen with shorter-acting therapies. The results, combined with the safety profile to date and pharmacodynamic activity observed, support the potential of MBX 2109 as a transformative treatment option for patients with #hypoparathyroidism.    We are excited to advance the development of MBX 2109 and anticipate completing enrollment in our Phase 2 Avail™ trial in Q1 2025, with topline results expected in Q3 2025.    Read more about the published study in JCEM here: https://lnkd.in/eh2gytmT   #endocrine 

Our Chief Executive Officer and Co-Founder, Kent Hawryluk, joined Nasdaq’s “Behind the Bell” series on the heels of our #IPO to discuss the exciting future ahead for MBX and how we are pioneering innovative medicines for #endocrine and #metabolic disorders. See the full video below and here: https://bit.ly/3CtOokS    #NasdaqListed $MBX 

Tomorrow, MBX Biosciences President & CEO Kent Hawryluk is presenting at the Jefferies London Healthcare Conference at 3:30 p.m GMT. Connect with us onsite, or tune into our webcast virtually at https://lnkd.in/g3mBBiBV #JefferiesHealthcare 

The last subject’s last visit is now complete in our Phase 1 trial of MBX 1416, a long-acting #GLP1 receptor antagonist in development for post-bariatric hypoglycemia (PBH). With no approved therapies for #PBH, this represents meaningful progress toward addressing an important unmet medical need for patients.     Topline results from the trial are expected in early January 2025. We thank the participants, investigators, and clinical team for their contributions to this program. View more information in the press release: https://lnkd.in/ecmYTm4K

Our Chief Executive Officer and Co-Founder, Kent Hawryluk, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 p.m. EST. We look forward to discussing the latest progress around our pipeline of #endocrine and #metabolic candidates and upcoming anticipated milestones. For those not attending, access the webcast and a replay at https://lnkd.in/g3mBBiBV  

The MBX Biosciences team is excited to participate at the Guggenheim Inaugural Healthcare Innovation Conference in Boston today. Our team will be sharing insights during a fireside chat at 3:30 p.m. EST. Tune in to learn more about our precision peptide therapies for #endocrine and #metabolic disorders.    View the live webcast and a replay at https://lnkd.in/g3mBBiBV

In celebration of STEM Day, we’re proud to highlight MBX Biosciences’ commitment to inspiring the next generation of innovators!    Through our ongoing #STEM initiatives, we’re dedicated to sparking curiosity in science, technology, engineering, and math—investing in the leaders of tomorrow who will drive the future of healthcare and patient care.    Join us in celebrating #STEMDay and the role STEM education plays in shaping a future of innovation and impact!     #FutureLeaders #STEMCareers #STEMDay2024

Today, we shared our inaugural #earnings release following our recent #IPO. View our Q3 highlights and upcoming milestones in the press release: https://lnkd.in/e6dNmQn8

Tomorrow, our Scientific Co-Founder, Richard DiMarchi, Ph.D., will be a keystone speaker at the 2024 BioCrossroads Life Sciences Summit in Indianapolis, where he will share insights around the latest innovations shaping #diabetes and #obesity care.    Our Senior Vice President, Discovery & Non-Clinical Development, Michael A. Dorato, PhD, DABT, Fellow ATS, FRSB will also be joining Ruth Gimeno, Ph.D., and Karen Wurster, MBA, for a panel discussion moderated by Dr. Janel Gordon, MD, DipABOM, DipABLM, exploring next generation approaches to diabetes and obesity management.    Don’t miss this opportunity to learn more about recent breakthroughs and forward-looking insights surrounding these #metabolic conditions. Register for the event here: https://bit.ly/3zPzRPA

Our Chief Medical Officer, Salomon (Sam) Azoulay, M.D., attended the HypoPARAthyroidism Association’s International HypoPARAthyroidism Conference this past weekend to share an overview of the Company and MBX-2109, our potential long-acting parathyroid hormone (PTH) peptide prodrug for the treatment of #hypoparathyroidism.   Check out photos from the conference where we shared how we’re working to redefine patient outcomes and enhance the quality of life for hypoparathyroidism patients everywhere.   #endocrine